Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04414930 · ClinicalTrials.gov registry record · Phase 2
Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia
A Phase 2 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT04414930 is a Phase 2 study that has completed, run by University of California, San Diego. The registered enrollment target is 68 participants.
The verdict
NCT04414930, a Phase 2 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
These studies look to conduct efficient pilot testing of a novel intervention strategy for chronic psychotic disorders - Pharmacologic Augmentation of Cognitive Therapy (PACT) - via an experimental medicine approach. Antipsychotics are the major therapeutic tool for chronic psychotic disorders, including schizophrenia, but do not significantly alter their course or real-life impact. Specific cognitive therapies achieve modest symptom reduction and improved function and cognition in psychosis patients, including "bottom-up" sensory-based targeted cognitive training (TCT). While benefits of TCT are evident at the group level, almost half of all patients demonstrate little or no cognitive gains after 30-40 hours (h) of TCT. For patients and clinicians, the costs and logistical complexities associated with these time- and resource-intensive interventions can be prohibitive. We propose and will test a novel "augmentation strategy" for using medications to specifically enhance the benefits of TCT in schizophrenia.
Interventions
- DRUG Placebo
- DRUG d-amphetamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2020-11-09 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04414930
The ClinicalTrials.gov registry entry for NCT04414930 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04414930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04414930 about?
NCT04414930 is a clinical study titled "Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia". These studies look to conduct efficient pilot testing of a novel intervention strategy for chronic psychotic disorders - Pharmacologic Augmentation of Cognitive Therapy (PACT) - via an experimental medicine approach. Antipsychotics are the major therapeutic tool for chronic psychotic disorders, incl...
What is the current status of trial NCT04414930?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2020-11-09. Estimated completion is 2024-12-30.
What interventions are being tested in trial NCT04414930?
The interventions under investigation include: Placebo (DRUG), d-amphetamine (DRUG).
Who is sponsoring clinical trial NCT04414930?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.